Package leaflet: Information for the user. Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion

Similar documents
Aminosteril N-Hepa 8%, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. PRESCRIPTION STATUS/RESTRICTION OF SALES TO PHARMACIES ONLY 3. COMPOSITION OF THE MEDICINAL PRODUCT ml of the solution for infusion contain:

PACKAGE LEAFLET: INFORMATION FOR THE USER. Nutriflex plus Solution for Infusion Amino acids / Glucose / Electrolytes

2. PRESCRIPTION STATUS/RESTRICTION OF SALES TO PHARMACIES ONLY 3. COMPOSITION OF THE MEDICINAL PRODUCT

PACKAGE LEAFLET: INFORMATION FOR THE USER. Nutriflex peri Solution for Infusion. Amino acids / Glucose / Electrolytes

Amino Acids and Sorbitol injection with/without Electrolytes NIRMIN *

PACKAGE LEAFLET: INFORMATION FOR THE USER. Glucose Intravenous Infusion BP 10% w/v solution for infusion Glucose (as glucose monohydrate)

Package leaflet: Information for the user. StructoKabiven emulsion for infusion

SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. SmofKabiven emulsion for infusion

Vamin 18 EF QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS. Synthamin 14, 8.5% Amino Acid Intravenous Infusion

Package leaflet: Information for the user. StructoKabiven Elektrolytfri emulsion for infusion

SUMMARY OF PRODUCT CHARACTERISTICS mg (6.85 mg)

PACKAGE LEAFLET: INFORMATION FOR THE USER. StructoKabiven Elektrolytfri emulsion for infusion

Package leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin

Package leaflet: Information for the user. Kabiven Peripheral, emulsion for infusion

Package leaflet: Information for the user. Kabiven, emulsion for infusion

Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride

Appendix E - Product Monograph Template Standard ver 1.0 Template Date: January 2010 Page 51 of 60

Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid

Package leaflet: Information for the patient. Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid

Package leaflet: Information for the user

Package leaflet: Information for the user. multibic potassium-free solution for haemodialysis/haemofiltration

Package leaflet: Information for the user. Nutriflex Omega plus Emulsion for infusion

Hartmann s Solution. For Infusion

Package leaflet: Information for the patient. Selenium 10 micrograms/ml concentrate for solution for infusion. Sodium selenite

The medicines you are using mixed with Water for injections may interact with each other.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

Package leaflet: Information for the user. Paralink 10 mg/ml Solution for Infusion Paracetamol

Package leaflet: information for the user. Prismasol 2 mmol/l Potassium Solution for haemodialysis/haemofiltration

2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE USER. Human Albumin Biotest 20%, solution for infusion Human albumin

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab

Package leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate

Package leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dopamine 40 mg/ml Sterile Concentrate

Potassium Chloride 0.3% w/v and Sodium Chloride 0.9% w/v Solution for Infusion Potassium chloride and sodium chloride

Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil

PACKAGE LEAFLET: INFORMATION FOR THE USER

SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the patient. Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion. Active substance: Heparin Sodium

PACKAGE LEAFLET: INFORMATION FOR THE USER. Actilyse Cathflo 2 mg, poeder voor oplossing voor injectie en infusie. Alteplase

Package leaflet: Information for the patient

Package leaflet: Information for the user Cyklokapron 500 mg Solution for Injection tranexamic acid

LEUCOVORIN-TEVA 10 mg/ml CONCENTRATE FOR SOLUTION FOR INFUSION folinic acid as the calcium salt PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER. Zoledronic Acid IBIGEN 4 mg powder and solvent for solution for infusion Zoledronic acid

PACKAGE LEAFLET: INFORMATION FOR THE USER. Variquel 1 mg powder and solvent for solution for injection Terlipressin acetate

2. What you need to know before you use Compound Sodium Lactate

Package leaflet: Information for the user. ReoPro 2 mg/ml solution for injection or infusion. abciximab

1. What Octostim Nasal Spray is and what it is used for

PACKAGE LEAFLET: INFORMATION FOR THE USER. SODIPHOS 22mEq / 10ml Concentrate for solution for infusion. Disodium phosphate dihydrate

Package leaflet: Information for the user

THORENS I.U. /2.5 ml oral solution. Cholecalciferol (vitamin D 3 )

PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER. chloroprocaine hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide Accord 20 mg/ml Concentrate for Solution for Infusion Etoposide

PACKAGE LEAFLET: INFORMATION FOR THE USER. Calcium Folinate 10 mg/ml Injection

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

SUMMARY OF PRODUCT CHARACTERISTICS. Medical conditions that require parenteral nutrition for supply of energy and essential fatty acids.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml solution for injection/infusion Cisatracurium 5 mg/ml solution for injection/infusion

Package leaflet: Information for the user. Numeta G19E emulsion for infusion

Package leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml Solution for Injection/Infusion Cisatracurium 5 mg/ml Solution for Injection/Infusion

Package leaflet: Information for the user

Package leaflet: Information for the user. Cyanokit 5 g powder for solution for infusion hydroxocobalamin

1. What Miacalcic is and what it is used for

PRODUCT INFORMATION. NAME OF MEDICINE VAMIN 14, VAMIN 14 Electrolyte Free and VAMIN 18 Electrolyte Free

Package leaflet: Information for the patient. Paracetamol 10 mg/ml solution for infusion. Paracetamol

Package leaflet: Information for the patient. Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER. octaplaslg mg/ml solution for infusion Human plasma proteins

PACKAGE LEAFLET: INFORMATION FOR THE USER. Zoledronic Acid 4 mg/5 ml concentrate for solution for infusion. Zoledronic acid

PRODUCT INFORMATION. NAME OF MEDICINE Glamin is an amino acid / dipeptide 13.4% solution for intravenous infusion.

Package leaflet: Information for the user. Bridion 100 mg/ml solution for injection sugammadex

Package leaflet: Information for the user. Lidocaine Hydrochloride 1% w/v Solution for Injection Lidocaine Hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Fibrovein 3%, 1%, 0.5% and 0.2% Solution for Injection Sodium tetradecyl sulphate

Package leaflet: Information for the patient. Lacosamide G.L. 10 mg/ml solution for infusion lacosamide

NITHIODOTE Solution for Injection. Active Substances Sodium Nitrite and Sodium Thiosulfate

Package leaflet: Information for the user

THORENS I.U. /ml oral drops, solution Cholecalciferol (vitamin D 3 )

PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin

Package leaflet: Information for the user

Product Information: Tyrex -1

Package leaflet: Information for the user. Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal)

Product Information: Propimex -1

Package leaflet: Information for the user. Nocdurna 25 microgram oral lyophilisate Nocdurna 50 microgram oral lyophilisate.

Package leaflet: Information for the user

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride

Package leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate

Package leaflet: Information for the user. Colecalciferol 3000 IU/ml Oral Solution (colecalciferol)

เอกสารกาก บยาภาษาอ งกฤษ. AVAXIM 160 U Suspension for injection in a prefilled syringe Hepatitis A vaccine (inactivated, adsorbed)

Cofact can be used for: The treatment of haemorrhages or the prevention of peri-operative haemorrhages as the result of

Ventolin Injection 500 micrograms/ml salbutamol sulfate

PACKAGE LEAFLET: INFORMATION FOR THE USER. Raloxifen STADA 60 mg film-coated tablets (raloxifene hydrochloride)

Transcription:

Package leaflet: Information for the user Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. If any of the side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effets not listed in this leaflet. See section 4. What is in this leaflet: 1. What Aminoven is and what it is used for 2. What you need to know before you receive Aminoven 3. How to use you minoven 4. Possible side effects 5. How to store Aminoven 6. Contents of the pack and other information 1. What Amionven is and what it is used for Aminoven provides nourishment straight into your blood stream when you cannot eat normally. It provides amino acids which your body will use to make proteins (to build and repair muscles, organs, and other body structures). Aminoven is typically mixed in a pharmacy with fat, carbohydrates, salts and vitamins, which together provide your complete nutritional needs. This leaflet covers 3 products: Aminoven 5% Solution for Infusion Aminoven 10% Solution for Infusion Aminoven 15% Solution for Infusion In this leaflet the three solutions are collectively referred to as Aminoven. 2. What you need to know before you receive Aminoven You should not receive Aminoven if you are suffering from, or have suffered from the following. Do not use Aminoven: if you have a condition where your body has problems using proteins or amino acids if you have metabolic acidosis (the acid levels of your body fluids and tissues become too high) if you have reduced kidney function and are not on dialysis or another form of blood filtration treatment if you have seriously reduced liver function inf you have fluid retention if you suffer from shock if you have hypoxia (low levels of oxygen) if you have a decompensated heart failure Aminoven 5% and 10% should not be used for children below 2 years of age. Aminoven 15% should not be used for children.

For children under 2 years, paediatric amino acid preparations which are formulated to meet their different metabolic needs should be used. Warnings and precautions Inform your doctor if you: suffer from low levels of potassium (hypokalaemia) suffer from low levels of sodium (hyponatraemia) suffer from folate deficiency suffer from heart failure (cardiac insufficiency) The doctor or nurse will check that the solution is particle free before usage. Other medicines and Aminoven Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Pregnancy and breast-feeding You should tell your doctor if you are pregnant, if you think you are pregnant or if you are breast-feeding. The doctor will decide if you should receive Aminoven. Driving and using machines Aminoven infusion has no effect on driving or using machines. 3. How to use Aminoven You will receive your medicine by infusion (IV drip). The amount and rate at which the infusion is given depends on your requirements. Your doctor will decide on the correct dose for you to receive. You may be monitored during your treatment. If you use more Aminoven than you should It is very unlikely that you will receive more infusion than you should as your doctor or nurse will monitor you during the treatment. The effects of an overdose may include nausea, vomiting and shivering. If you experience these symptoms or believe that you have received too much Aminoven inform your doctor or nurse immediately. If you have any further questions on the use of this product, ask your doctor or pharmacist. 4. Possible side effeccts Like all medicines, Aminoven can cause side effects, although not everybody gets them. The following side effects have been observed when infusion was administered too quickly: loss of potassium or sodium from the blood folate deficiency At the site of injection the following side effects may occur: soreness and tenderness of the vein thrombosis (the formation of a clot) in the vein where the injection is given Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via www.xxx.xx.xx. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Aminoven Keep this medicine out of the reach and sight of children. Your doctor and hospital pharmacist are responsible for the correct storage, use and disposal of Aminoven infusion. Do not freeze and always keep the container in the outer carton. The solution must not be used after the expiry date shown on the label. Any solution remaining after treatment should be disposed of via approved hospital procedures. 6. Contents of the pack and other information What Aminoven solution for infusion contain Each 1000 ml of Aminoven contains the following active ingredients: Active ingredients Quantity (g) Aminoven 5% Aminoven 10% Aminoven 15% Isoleucine 2.50 5.00 5.20 Leucine 3.70 7.40 8.90 Lysine acetate 4.655 9.31 15.66 Methionine 2.15 4.30 3.80 Phenylalanine 2.55 5.10 5.50 Threonine 2.20 4.40 8.60 Tryptophan 1.00 2.00 1.60 Valine 3.10 6.20 5.50 Arginine 6.00 12.00 20.00 Histidine 1.50 3.00 7.30 Alanine 7.00 14.00 25.00 Glycine 5.50 11.00 18.50 Proline 5.60 11.20 17.00 Serine 3.25 6.50 9.60 Tyrosine 0.20 0.40 0.40 Taurine 0.50 1.00 2.00 Aminoven 5% and Aminoven 10% also contain glacial acetic acid and water for injections. Aminoven 15% also contains glacial acetic acid, water for injections and malic acid. What Aminoven looks like and contents of the pack Aminoven 5% and Aminoven 10% are available in colourless glass bottles with a rubber closure/aluminium cap that contain 500 ml or 1000 ml of solution. Aminoven 15% is available in colourless glass bottles with a rubber closure/aluminium cap that contain 250 ml, 500 ml or 1000 ml of solution. Not all pack sizes may be marketed. Marketing Authorisation Holder [To be completed nationally] Manufacturer Aminoven in glass bottles is manufactured by: Fresenius Kabi Austria GmbH Hafnerstrasse 36 A-8055 Graz

Austria This leaflet was last revised in {MM/YYYY}. [To be completed nationally] ----------------------------------------------------------------------------------------------------------------------------- The following information is intended for healthcare professionals only: Posology and method of administration The daily requirement of amino acids depends on the body weight and the metabolic conditions of the patient. The maximum daily dose varies with the clinical condition of the patient and may even change from day to day. The recommended infusion period is to provide a continuous infusion for at least 14 hours up to 24 hours, depending on the clinical situation. Bolus administration is not recommended. The solution is administered as long as a parenteral nutrition is required. Aminoven 5%: For administration via a peripheral or central vein as a continuous infusion. The usual daily dose Aminoven 5% is 16-20 ml of per kg body weight (equivalent to 0.8-1.0 g amino acids per kg body weight) e.g. corresponding to 1120-1400 ml Aminoven 5 % at 70 kg body weight. Maximum infusion rate is 2.0 ml of Aminoven 5% per kg body weight per hour (equivalent to 0.1 g amino acids per kg body weight and hour). Maximum daily dose to adults 20 ml of Aminoven 5% per kg body weight/day (equivalent to 1.0 g amino acids per kg body weight) e.g. corresponding to 70 g amino acids at 70 kg body weight. For an increased amino acids dosage suitable preparations are available. Maximum daily dose to children and adolescents (2-18 years) 40 ml of Aminoven 5% per kg body weight/day (equivalent to 2.0 g amino acids per kg body weight/day) but total daily fluid intake must be considered. Aminoven 10%: For administration via a central vein as a continuous infusion. The usual daily dose Aminoven 10% is 10-20 ml per kg body weight equivalent to 1.0-2.0 g amino acids per kg body weight) e.g. corresponding to 700-1400 ml Aminoven 10% at 70 kg body weight. Maximum infusion rate is 1.0 ml of Aminoven 10% per kg body weight per hour (equivalent to 0.1 g amino acids per kg body weight and hour). Maximum daily dose to adults, adolescents and children (from 2 years) 20 ml of Aminoven 10% per kg body weight/day (equivalent to 2.0 g amino acids per kg body weight) e.g. corresponding to 1400 ml Aminoven 10% or 140 g amino acids at 70 kg body weight. Aminoven 15%: For administration via a central vein as a continuous infusion. The usual daily dose Aminoven 15% is 6.7-13.3 ml per kg body weight (equivalent to 1.0-2.0 g amino acids per kg body weight) corresponding to 470 to 930 ml Aminoven 15% at 70 kg body weight. Maximum infusion rate is 0.67 ml of Aminoven 15% per kg body weight and hour (equivalent to 0.1 g amino acids per kg body weight and hour). Maximum daily dose to adults 13.3 ml of Aminoven 15% per kg body weight/day (equivalent to 2.0 g amino acids per kg body weight) e.g. corresponding to 140 g amino acids at 70 kg body weight. Aminoven 15% is contraindicated in children.

Overdose (symtoms, emergency procedure, antidotes): As with other amino acid solutions shivering, vomiting, nausea, and increased renal amino acid losses can occur when Aminoven is given in overdose or the infusion rate is exceeded. Infusion should be stopped immediately in this case. It may be possible to continue with a reduced dosage. A too rapid infusion can cause fluid overload and electrolyte disturbances. Emergency procedures should be general supportive measures, with particular attention to respiratory and cardiovascular systems. Close biochemical monitoring would be essential and specific abnormalities treated appropriately. There is no specific antidote for overdose. Storage Keep out of the reach and sight of children. Keep container in the outer carton. Do not store above 25 C. Do not freeze. Use only clear, particle-free solutions and undamaged containers. Do not use Aminoven after the expiry date which is stated on the label after Expiry Date. The expiry date refers to the last day of that month. Aminoven should be used with sterile transfer equipment immediately after opening. Any unused solution should be discarded. Aminoven may be aseptically admixed with other nutrients such as fat emulsions, carbohydrates and electrolytes. Chemical and physical stability data for a number of admixtures stored at 4 C for up to 9 days are available from the manufacturer upon request. From a microbiological point of view, TPN admixtures compounded in uncontrolled or unvalidated conditions should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should normally be no longer than 24 hours at 2 to 8 C, unless mixing has taken place in controlled and validated aseptic conditions.